-
MGI Tech and Haihe Laboratory Deepen Collaboration with Introduction of CycloneSEQ-WT02
•
MGI Tech Co., Ltd, a prominent gene sequencing company based in China, has disclosed a previous collaboration with the Haihe Laboratory of Cell Ecosystem under the China Academy of Medical Sciences, which commenced under the ‘SEQ ALL’ multi-omics initiative. This partnership initially led to the establishment of a multi-omics DCS…
-
MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research
•
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has entered into a strategic partnership with fellow Chinese firm Sequanta Technologies Co., Ltd, marking a significant step with the establishment of the “Sequanta-MGI DCS Lab.” The DCS Lab is a state-of-the-art facility equipped with cutting-edge technology, including…
-
China Boosts Public Health Subsidies and Targets Weight Management in 2024
•
The National Health Commission, Ministry of Finance, National Administration of Traditional Chinese Medicine, and National Disease Control and Prevention Administration in China have jointly issued a notification to enhance basic public health services for the current year. The subsidy standard for per capita funding for basic public health services will…
-
China’s NHSA and MOF Issue Notices to Enhance Cross-Regional Medical Treatment Direct Settlement
•
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MOF) have issued two key notices aimed at enhancing the healthcare system in China. The first, ‘Notice on Further Strengthening the Management Service of Direct Settlement for Medical Treatment Incurred in Other Regions,’ outlines several measures to improve the…
-
CDE Launches CARE Plan to Streamline Rare Disease Drug Development
•
The Center for Drug Evaluation has unveiled the ‘Pilot Work Plan for Patient-Centered Action for Rare Diseases Encouragement (CARE),’ following a public consultation period in May 2024. The final document retains the initial proposal’s structure, segmenting the drug R&D lifecycle into stages A through E, with the anticipation of including…
-
Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment
•
Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced a strategic realignment during its investor R&D day, reflecting a broader trend among multinational corporations (MNCs) to streamline operations. The company has committed to a program that includes cost-cutting measures and a reprioritization of its…
-
Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery
•
Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an expansion of their partnership to harness generative artificial intelligence (AI) for drug discovery. While the financial details of the deal remain undisclosed, the collaboration aims to combine Sino Bio’s advanced protein expression and wet-lab expertise…
-
Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis
•
Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported a second New Drug Application (NDA) filing for its FcRn blocker, nipocalimab. The company has submitted the application to the European Medicines Agency (EMA) for the treatment of adults with generalized myasthenia gravis (gMG) who…
